| Q37586580 | Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease? |
| Q39100810 | Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies |
| Q38871200 | CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features |
| Q45903141 | Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis. |
| Q64054802 | Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases |
| Q42050224 | Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease |
| Q42376403 | Expression of CCR3, SOX5 and LC3 in patients with elderly onset rheumatoid arthritis and the clinical significance |
| Q57494703 | Highlights from the 2018 European Respiratory Society Congress presentations on interstitial lung diseases |
| Q58747855 | Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis |
| Q40289711 | Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year |
| Q89936679 | Imaging research in fibrotic lung disease; applying deep learning to unsolved problems |
| Q58798399 | Investigation of key autophagy-and mitophagy-related proteins and gene expression in BALF cells from patients with IPF and RA-ILD |
| Q55361229 | Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment. |
| Q39335156 | Lung Manifestations in the Rheumatic Diseases |
| Q57808775 | MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease |
| Q90106982 | Management issues in rheumatoid arthritis-associated interstitial lung disease |
| Q92914293 | Mechanisms of lung disease development in rheumatoid arthritis |
| Q90130855 | Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial |
| Q40430551 | Patterns of interstitial lung disease and mortality in rheumatoid arthritis. |
| Q60921512 | Predicting outcomes in rheumatoid arthritis related interstitial lung disease |
| Q90263056 | Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease |
| Q93036315 | Progression of fibrosing interstitial lung disease |
| Q47965960 | Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease. |
| Q97538790 | RA-ILD: does more detailed radiological classification add something to our knowledge of this condition? |
| Q47769077 | Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease. |
| Q38678939 | Recent advances in connective tissue disease related interstitial lung disease |
| Q50101241 | Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts |
| Q52940652 | Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. |
| Q90396157 | Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population |
| Q90260152 | Rituximab in connective tissue disease-associated interstitial lung disease |
| Q33737250 | Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF). |
| Q92645330 | Role of lentivirus-mediated overexpression of SOCS3 in proliferation and apoptosis of fibroblasts-like synoviocytes in Lewis rats with adjuvant-induced rheumatoid arthritis |
| Q97538814 | The challenges in classifying rheumatoid arthritis-associated interstitial lung disease |
| Q64095504 | The natural history of progressive fibrosing interstitial lung diseases |
| Q90689112 | The natural history of progressive fibrosing interstitial lung diseases |
| Q38787176 | The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease |
| Q92384589 | Thoracic Manifestations of Rheumatoid Arthritis |
| Q36086758 | Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes. |
| Q57176235 | [What rheumatologists can learn from pneumologists] |